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Increased Skeletal Muscle Amino Acid Release With Light Exercise in
Deconditioned Patients With Heart Failure
To the Editor: The existence of muscle metabolic alterations in
patients with chronic heart failure (CHF) (1) led us to test the
hypothesis that even a light exercise mimicking a daily life activity
(2) in CHF may induce an excess of muscle amino acid release. We
focused in particular on phenylalanine (Phe) release because this
amino acid is neither synthesized nor degraded within muscle (3).
Twenty untrained, clinically stable, normonourished fasting
male patients (Table 1) with moderate to severe CHF at morning
underwent hemodynamic procedures to measure femoral blood
flow, arterial and venous amino acid concentrations (branched
chain amino acids [BCAAs: valine, leucine, isoleucine], histidine,
alanine, glutamic acid, glutamine, and taurine), as well as pH and
lactate and free fatty acid (FFA) levels both at baseline and at 20
W bicycle exercise oxygen consumption (VO2, ml·kg
1·min1)
steady state.
The net uptake and/or release of muscle amino acids was
calculated as: Net balance  ([A]  [V])  F where A  V is the
femoral arteriovenous difference in amino acid concentrations and
F is leg blood flow. Thus, a net muscle uptake means amino acid
utilization, whereas a net muscle release indicates increased protein
breakdown and/or amino acid alteration.
At rest, controls and CHF had similar arterial amino acid concen-
trations (unpaired t test). Net muscle uptake and/or release of amino
acids by controls and CHF, at rest and during exercise, are illustrated
in Figure 1. At rest, CHF took up all amino acids except taurine,
which was released, whereas controls released amino acids with the
exception of glutamic acid and taurine, which were taken up. During
exercise, CHF, but not controls, released significant amounts of Phe
(from 38.2  2.4 to 42.3  3.2 mol·l1·min1; p  0.01), the
three BCAAs; histidine, alanine (p 0.05 in all cases), and glutamine
(p  0.01). The uptake of glutamic acid declined (p  0.01) and
taurine was taken up (p  0.01), resulting in levels higher than in
controls (p  0.05) (paired t test).
At rest, arterial FFA concentration as well as FFA release was
higher in CHF than in controls (p 0.05 and0.001, respectively).
During exercise the difference in FFA release between CHF and
controls declined but remained significant (p  0.01). At rest, blood
femoral vein was acidotic in CHF (pH 7.34 0.02 vs. 7.41 0.01
in controls; p  0.05); during the effort, the pH of CHF further
decreased (7.31  0.01; p  0.01).
This investigation shows that patients with CHF exercising at a
light workload have a net muscle release of both Phe and other
amino acids. The mechanisms responsible for the net release of
Phe during exercise in CHF patients may include alterations in
intermediary and energy metabolism within muscle cells, intracel-
lular acidosis, and cytokine production. Indeed, the low intramus-
cular glycogen concentration in resting CHF patients (4) may
make muscle energy metabolism more dependent on alternative
substrates such as amino acids derived from cellular-free pool
Table 1. Clinical, Functional, Hemodynamic, and Hormonal
Characteristics of Controls and CHF Patients
Parameters
Controls
(n  10)
Patients
(n  20)
Age (yrs) 60.2  2.1 59.5 2.5
Weight (kg) 70.5 3.5 72.3 9.1
Duration of disease
18 months — 8/20
18 months — 12/20
NYHA functional class II/III — 12/8
Medications
ACE inhibitors — 17/20 (85%)
Digoxin — 7/20 (35%)
Diuretics — 20/20 (100%)
Oral nitrates — 8/20 (40%)
Left ventricular ejection fraction (%) 56.5  1.5 22  0.9*
Peak VO2 (ml·kg
1·min1) 33.3  1.4 13.5  0.4*
Cardiac index (l·min1·m2) — 2.16  0.15
Pulmonary wedge pressure (mm Hg) — 17.6  2.5
Right atrial pressure (mm Hg) — 6.7  0.9
Hemoglobin (g·dl1) 14.1  0.8 13.3  0.11
Noradrenaline (pg·ml1) 278  72 412  22*
Serum sodium level (mEq·l1) 140  5 136  3
Arterial lactate concentration (mg·dl1) 3.9  1.1 4.3  1.2
Midarm muscle area (cm2) 46  2.1 46.0  1.6
Values are expressed as mean  SEM. Statistical analysis: unpaired t test controls vs.
patients. *p  0.01.
ACE  angiotensin-converting enzyme; CHF  congestive heart failure; NYHA
 New York Heart Association.
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and/or accelerate protein degradation. Carbohydrate depletion, in
fact, favors muscle protein breakdown, whereas carbohydrate
loading significantly restricts protein degradation (5). Further-
more, the documented glycolytic and oxidative pathway alterations
in CHF (4) could contribute to increasing muscle protein utiliza-
tion and amino acid oxidation.
The muscle metabolic acidosis can worsen the net negative
balance of Phe in CHF; this is because low pH acts as a catabolic
stimulus in normal adults (6). Notably, the acidosis in our CHF
patients may be enhanced by the net loss of muscle histidine, the
main intracellular buffer in the muscle. A possible cytokine
overproduction in exercising CHF may also contribute to release of
Phe from muscles (7). The release of BCAAs confirms the
existence of abnormal amino acid metabolism in exercising CHF
because exercise normally causes muscle to extract BCAAs from
the plasma and not to release them into the bloodstream (8).
The finding of a positive net balance of muscle amino acids
(with the exception of glutamic acid), particularly of alanine, in
resting overnight fasting CHF is the opposite of what occurred in
controls, insulin activity being normally low after overnight fasting.
It is likely that a normal availability of arterial amino acids in CHF
patients, together with increased serum catecholamine levels, may
have counteracted muscle release of amino acids in the fasting state
(9,10). During exercise, CHF patients release alanine, as do
normal subjects at rest.
The persistence of muscle glutamic acid uptake, the increased
glutamine release, and the increased taurine uptake may all indicate
an increased muscle utilization of these amino acids by CHF
during exercise (11,12). The release of FFA may suggest that, in
CHF, an increased muscle lipolysis also occurred (13).
In brief, the study shows that, during light exercise, untrained
patients with CHF release a number of muscle amino acids,
suggesting a possible abnormal muscle amino acid metabolism.
Based on these data and on Phe release (3) we hypothesize an
occurrence of muscle protein overdegradation in deconditioned
exercising CHF. If so, it is conceivable that repeated daily-life
physical activities by untrained CHF patients may contribute to a
negative nitrogen balance (14) and to muscular wasting.
Finally, in this context appropriate physical training can coun-
teract muscle amino acid release and protein degradation in
untrained CHF (15).
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Figure 1. Muscle amino acid net uptake and/or release (mol·l1·min1)
at rest and during light exercise (20 W) in controls (open bars) and chronic
heart failure (CHF) patients (solid bars).
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Letters to the Editor
Cautious Interpretation of
Data Regarding Myopericarditis
Associated With Smallpox Vaccination
We congratulate Cassimatis et al. (1) for their excellent review of
myopericarditis associated with smallpox vaccination. We suggest
a different interpretation of the data regarding some important
issues.
First, the true incidence of myopericarditis secondary to small-
pox vaccination with Dryvax (NYBOH strain) vaccine remains
unknown and it is likely higher than the quoted rates of one case
per 9,360 (1), 10,000 (2), or 12,819 (3) vaccinations, which
represent the recognition of overt, symptomatic myopericarditis in
a highly selected, very fit military population. We suspect myo-
pericarditis is underdiagnosed in this population because of the
wide spectrum of presenting clinical symptoms and signs that
confound accurate diagnosis, the potential for minimal or no-
symptom cases that could lead to missed cases, and the character-
istics of young, volunteer, military personnel who could conceiv-
ably overlook or minimize symptoms that do not limit their service
duties. A higher rate of myopericarditis is supported by the 2% to
3% incidence of electrocardiographic changes after smallpox vac-
cination in Swedish military personnel in the 1960s (4,5). Impor-
tantly, a higher incidence of myopericarditis would likely be
recognized if mass smallpox vaccination were applied to the
general population with higher prevalence rates of cardiovascular
and immunologic disease, in an attempt to protect citizens against
smallpox bioterrorism.
Second, the long-term sequelae of myopericarditis due to
smallpox vaccination remain unknown. Subclinical or overt abnor-
malities due to vaccinia viremia or its immunologic responses, such
as direct viral toxicity or immune-mediated myocyte necrosis,
persistent myocardial inflammatory infiltrates, or development of
myocardial fibrosis, may manifest years later, with ventricular
dysfunction, conduction system abnormalities, or sudden death.
Although almost all recently vaccinated patients with myopericar-
ditis recovered clinically, the possibility of residual low-grade
myocardial inflammation and fibrosis cannot be excluded or
prevented.
Third, endomyocardial biopsy probably is of greater than
“limited utility” after smallpox vaccination. We advocate endo-
myocardial biopsy for all patients with suspected new-onset ven-
tricular dysfunction (ejection fraction 45%) and symptoms of
heart failure after smallpox vaccination. The rationale for this
approach is the documentation of possible steroid responsive
eosinophilic myocarditis, which occurred in one recent patient
after smallpox vaccination, and the need to exclude uncontrolled
vaccinia virus replication within the myocardial that may be
responsive to immune globulin. Endomyocardial biopsy under
echocardiographic guidance is a relatively safe procedure in expe-
rienced hands and may provide a definitive actionable diagnosis in
high-risk patients (6).
It is a profound tragedy that vaccination against an eradicated
disease whose elimination marked the single greatest human
success against a communicable disease is now required for U.S.
soldiers because of the threat of biowarfare. Current smallpox
vaccine appears to carry significant risks of serious adverse events.
The true incidence and long-term sequalae of current smallpox
vaccine remain unknown.
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REPLY
We appreciate the comments on our review (1) of myopericarditis
associated with smallpox vaccination. The recently published rates
of myopericarditis may indeed be underestimates, for they are
based on reporting of clinical encounters with symptomatic pa-
tients from an occupational cohort, as we noted previously (2). To
better assess the true incidence rate, we will soon enroll volunteers
in a prospective trial of smallpox vaccinees with baseline and
follow-up electrocardiography, laboratory markers, and question-
naires.
We described the need to follow patients diagnosed with
postvaccinial myopericarditis to establish whether long-term se-
quelae exist (1), and we recently have published the results of such
follow-up (3). On the basis of these data, long-term sequelae are
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